Wall Street Analysts See a 92.12% Upside in Ardelyx (ARDX): Can the Stock Really Move This High?Zacks Investment Research • 01/06/26
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney WeekGlobeNewsWire • 11/07/25
Ardelyx to Participate at the Jefferies Global Healthcare Conference in LondonGlobeNewsWire • 11/05/25
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor ConferenceGlobeNewsWire • 11/04/25
Ardelyx (ARDX) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 10/30/25
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 10/30/25
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual MeetingGlobeNewsWire • 10/28/25
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney WeekGlobeNewsWire • 10/21/25
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial OfficerGlobeNewsWire • 10/13/25
Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/08/25
Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference TranscriptSeeking Alpha • 09/03/25
Ardelyx (ARDX) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/04/25
Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/04/25